Biotech Values

[DewDiligence]

I presume you’re referring to GILD’s statement that 70% of early Sovaldi sales were for GT1 patients (#msg-96799945). For ENTA investors, I consider this factoid less consequential than the disclosures discussed in #msg-96802014 because: i) the 70% figure comes from a very small sample and may be unreliable; and ii) what happens during the current window prior to all-oral approvals in late 2014/early 2015 matters less to ENTA’s valuation that what happens during the multi-year period after the two all-oral regimens are approved.